Evidence map›Paper›PMID 42063202›Full record

ArticlePilot and feasibility studies2026

An open-label, clinical feasibility study of the efficacy of Remdesivir for Long-COVID.

Helen Neilens, Victoria Allgar, Kayle-Anne Sands, Jade Chynoweth, Amber Lord, Paigan J Aspinall, Helen Hambly, Anton Barnett, Lindsay Skipper, Tom Bewick and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pilot and feasibility studies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05911906 (An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05911906 phase4completednot on this map

An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.

TypeinterventionalSponsorUniversity of DerbyRan2024 to 2025Enrolled73ConditionsSARS-CoV-2 Infection, COVID-19ArmsRemdesivir
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Helen NeilensPeninsula Clinical Trials Unit, University of Plymouth, Plymouth, UK. helen.neilens-1@plymouth.ac.uk.ORCID http://orcid.org/0000-0002-8288-0261
Victoria AllgarPeninsula Clinical Trials Unit, University of Plymouth, Plymouth, UK.
Kayle-Anne SandsPeninsula Clinical Trials Unit, University of Plymouth, Plymouth, UK.
Jade ChynowethMedical Statistics Group, University of Plymouth, Plymouth, UK.
Amber LordPeninsula Clinical Trials Unit, University of Plymouth, Plymouth, UK.
Paigan J AspinallPeninsula Clinical Trials Unit, University of Plymouth, Plymouth, UK.
Helen HamblyPeninsula Clinical Trials Unit, University of Plymouth, Plymouth, UK.
Anton BarnettMedical Statistics Group, University of Plymouth, Plymouth, UK.
Lindsay SkipperCollege of Science and Engineering, University of Derby, Derby, UK.
Tom BewickUniversity Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.
Ian MaidmentCollege of Health and Life Sciences, Aston University, Birmingham, UK.
Hairil Abdul RazakUniversity of Exeter, Exeter, UK/University of Exeter Medical School, Exeter, UK.
Ruth AshtonCollege of Science and Engineering, University of Derby, Derby, UK.
David StrainUniversity of Exeter, Exeter, UK/University of Exeter Medical School, Exeter, UK.
Karen KnappUniversity of Exeter, Exeter, UK/University of Exeter Medical School, Exeter, UK.
Mark A FaghySport and Exercise Sciences, Coventry University, Coventry, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong COVID (LC) affects around two million people in the UK and over 65 million people globally. Antiviral medications have shown positive effects in reducing the risk of progression to severe disease in high-risk patients during an acute SARS-CoV-2 infection and have improved outcomes in those living with LC. Research testing the feasibility and efficacy of antiviral medications is ongoing, and clinical trials should determine the use of Remdesivir and its impact on LC symptoms, patient-reported outcomes, quality of life and functional status.

methodsSeventy-two patients ≥ 18 years of age who have a confirmed LC diagnosis will be recruited across two sites to trial Remdesivir DISCUSSION: This study will provide data on the feasibility of a trial of 5-day intravenous treatment with Remdesivir for patients with LC. The treatment is already effective in the treatment of patients with acute severe cases of SARS-CoV-2. Remdesivir has an established safety profile and carries no higher risk to patients than standard medical care. The findings will inform the design of a future definitive study.

trial registrationISRCTN Number: 72940450. Date registered: 07/06/2024. URL: https://www.isrctn.com/ISRCTN72940450 . CLINICALTRIALS: gov Number: NCT05911906.

Indexed as

Covid-19EfficacyFeasibilityLong COVIDRemdesivirSafety

Identifiers

PMID42063202
PMCPMC13281550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.